# Study of Bevacizumab and Erlotinib in Patients With Advanced Non-small Cell Lung Cancer

> **NCT00553800** · PHASE2 · COMPLETED · sponsor: **Fox Chase Cancer Center** · enrollment: 32 (actual)

## Conditions studied

- Carcinoma, Non-Small-Cell Lung

## Interventions

- **DRUG:** bevacizumab
- **DRUG:** Erlotinib

## Key facts

- **NCT ID:** NCT00553800
- **Lead sponsor:** Fox Chase Cancer Center
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2007-07-05
- **Primary completion:** 2011-01-12
- **Final completion:** 2011-06-01
- **Target enrollment:** 32 (ACTUAL)
- **Last updated:** 2022-07-12

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00553800

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00553800, "Study of Bevacizumab and Erlotinib in Patients With Advanced Non-small Cell Lung Cancer". Retrieved via AI Analytics 2026-07-26 from https://api.ai-analytics.org/clinical/NCT00553800. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*